Scorpion Therapeutics is a biotechnology company that aims to bring precision medicine to a larger population of cancer patients. The company combines techniques from target discovery, medicinal chemistry, and translational medicine to create a range of targeted small-molecule drugs that surpass the constraints of current treatments. By implementing a fit-to-purpose model, Scorpion Therapeutics efficiently paves the way for the future of precision oncology, empowering healthcare professionals to provide cancer patients with innovative treatment options.
Omega Funds, Mass General Brigham Ventures, Nextech Invest, Abingworth, Fidelity Management & Research, Willett Advisors, Atlas Venture, Olive Tree Capital, Citadel Enterprise Americas, Frazier Healthcare Partners, Boxer Capital, Lightspeed Management Company, Surveyor Capital, OrbiMed, Casdin Capital, The Invus Group, Revelation Partners, Vida Ventures (Boston), Hillhouse Investment Group, EcoR1 Capital, Logos Capital, Woodline Partners, Mass General Brigham Innovation, Janus Henderson Investors, Wellington Management.